ZYBERNO
Stock Report
Updated Jun 8, 2026

T2 BIOSYSTEMS, INC. (TTOO)

Healthcare • Over The Counter

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
T2 BIOSYSTEMS, INC. (TTOO) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-542.6%)
Return on Capital (Capital Efficiency):CRITICAL (-195.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

T2 BIOSYSTEMS, INC. (TTOO) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$35.79K

Valuation Multiples (2)

P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$4.97M
B. Profitability Assessment

Return Metrics (4)

ROA:-172.9%
Reinvestment Rate:2.8%
Fundamental Growth Rate (g):-5.4%

Margin Analysis (3)

Operating Margin Ttm:-542.6%
Net Margin Ttm:-559.5%
Ebitda Margin:-538.2%

TTM Performance (2)

Operating Margin Ttm:-542.6%
Net Margin Ttm:-559.5%

Yield Metrics (2)

Earnings Yield:-$910.50K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:87.9%
Latest Earnings Filed:2024-11-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-38.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.40x
Quick Ratio:0.24x
Cash Ratio:0.09x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-14,649,000.00
Cash And Cash Equivalents:2,083,000.00
Long Term Debt:$5.30M
Net Debt:$4.94M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $7.68M
Linear Growth: -38.8%
📊 Click to view full TTOO Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$41.66M

Bottom Line Performance (3)

-$42.95M
Income Before Tax:$0.00
Ebitda Ttm:-41,317,000.00

Operating Expenses (5)

Operating Expenses:49,332,000.00
R And D Expense:12,918,000.00
Sga Expense:22,844,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:650.8%
Sga To Revenue Percentage:1,150.8%
Ebitda Margin:-538.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$18.08M
Current Assets:$9.79M
Ppe Net:16,481,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:29,792,000.00
Current Liabilities:24,435,000.00
Long Term Debt:$5.30M
Short Term Debt:$1.72M

Equity & Capital (3)

Equity:-$11.71M
Retained Earnings:-$616.91M
Common Stock:400,000,000.00

Working Capital Items (3)

Accounts Receivable:2,033,000.00
Inventory:3,825,000.00
Accounts Payable:4,210,000.00

Special Items (2)

Contract Liabilities:300,000.00
Stock Based Compensation:215,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$46.88M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$2.20M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:338,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-18.21
-$18.21
Earnings Per Share Ttm:-$2.40

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.43
Operating Cash Flow Per Share:-$2.69

Book Value & Capital (2)

Book Value Per Share:-$0.65
Cash Per Share:0.12

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.31x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:3.78x
Days Sales Outstanding Ttm:96.66

Inventory Management (2)

Inventory Turnover Ttm:2.01x
Days Inventory Outstanding Ttm:181.86

Payables & Cash Cycle (2)

Days Payable Outstanding:200.16
Cash Conversion Cycle:78.35
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.8%
Fundamental Growth Rate (g):-5.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-38.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:TTOO
Company Name:T2 BIOSYSTEMS, INC.
Sector:Healthcare
Industry:Medical Devices
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:17.89M
Shares Outstanding Basic:17.89M
Shares Outstanding Diluted:17.89M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 11:40:43 UTC
Data Timestamp:2026-06-08T11:40:43.311860
Scroll to Top